Altor Fund IV and Goldman Sachs set to buy Hamlet Protein

Polaris Private Equity and the Hamlet Protein’s founder Ole K. Hansen, are both exiting the company, according to reports. (Image source: Hamlet Protein)

Altor Fund IV and Goldman Sachs Merchant Banking Division have partnered to acquire majority share of Hamlet Protein from Polaris Private Equity

Currently, Polaris Private Equity owns 55 per cent share, founder Ole K. Hansen owns 41 per cent and others own four per cent.

Hamlet Protein is a provider of soy-based protein solutions used in high value-add animal feed for young animals. The company services more than 50 countries from its two production facilities in Horsens, Denmark and Findlay, Ohio.

Hamlet Protein CEO Søren Munch said, “With the strong support of Altor Fund IV and Goldman Sachs Merchant Banking Division we are uniquely positioned to accelerate the development and growth of Hamlet Protein and service our customers and partners better.”

Hansen added that it had been a successful partnership with Polaris Private Equity and they have managed to achieve a great development for Hamlet in the recent years.

“We have made a successful management succession and turned Hamlet Protein into a leading global provider of specialty soya for young animal feed with a strong market position in Europe, USA and Asia through developing global sales organisation and significant investments in expanding capacity including establishing a sales and production facility in the USA,” added Niels Worning, partner at Polaris Private Equity.

According to Søren Johansen, partner at Altor Equity Partners, Hamlet Protein is ideally positioned to become the global champion within high value-add young animal feed.

Michael Specht Bruun, managing director of Merchant Banking Division of Goldman Sachs, noted, “We see significant growth potential globally and are excited about partnering with Altor Fund IV and the management team to support the company’s impressive growth trajectory both organically and through acquisitions.”

Closing of the transaction is subject to customary regulatory requirements and approvals, the companies added.